INFLUENCE OF A CHOSEN AUXILIARY SUBSTANCE ON THE PROPERTIES OF HYDROPHILIC POWDERS CONTAINING LACTIC ACID COMPLEXED WITH CHITOSAN

• Authors: Katarzyna Małolepsza-Jarmołowska
• Languages of publication: EN EN

Abstracts

EN

Hydrophilic powders passing gels containing lactic acid complexed with chitosan at a stoichiometric ratio of 1:1 and 8:1 revealed pH ranged from 3.92 to 4.44 and 2.36 to 2.84. Rheological studies demonstrated that the research gels obtained from powders possess the dynamic viscosity ranging from 53 to 398 mPa.s for the 1:1 stoichiometric ratio in the complex and from 19 to 242 mPa.s for the 8:1 ratio. As a result of the research, preparations with different pH values, including physiological range, were obtained. Powders show that the adhesion of the gel covering the surface of the apparatus simulates the conditions in the vagina. The gels obtained from the powders were characterised by the specific dynamic viscosity and possess the work of adhesion. The results obtained in the experimental studies proved that it is possible to produce a preparation with optimal pharmaceutical and application properties.

Keywords

EN

anti-inflammatory drugs; hydrophilic powders passing gels; lactic acid complexed with chitosan; physiological environment of vagina; vaginal infections; vaginal mucosa

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Publisher: Sieć Badawcza Łukasiewicz - Polskie Towarzystwo Chitynowe
• Journal: Progress on Chemistry and Application of Chitin and its Derivatives
• Year: 2014
• Volume: 19
• Pages: 87-93

Contributors

author

Katarzyna Małolepsza-Jarmołowska

• Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy The “Silesian Piasts” Memorial Medical University of Wroclaw,

References

• 1. Schwebke JR; (2009) New concepts in the aetiology of bacterial vaginosis. Curr. Infect. Dis. Rep. 11, 143 – 147, DOI: 10.1007/s11908-009-0021-7 .
• 2. Brandt M, Abels C, May T, Lohmann K, Schmidts – Winkler I, Hoyme UB; (2008) Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur. J. Obstet. Gynecol. Reprod. Biol. 141, 158 – 162, DOI: 10.1016/j. ejogrb.2008.07.022.
• 3. Donders GGG, Larson PG, Platz – Christensen JJ, Hallen A, Meijden W, Wölner – Hanssen P; (2009) Variability in diagnosis of clue cells, lactobacillary grading and white blood cells in vaginal wet smears with conventional bright light and phase contrast microscopy. Eur. J. Obstet. Gynecol. Reprod. Biol. 145, 109 – 112, DOI: 10.1016/j.ejogrb.2009.04.012.
• 4. Kubis AA, Małolepsza-Jarmołowska K; (1996) Studies on gynaecological hydrophiling preparations comprising lactic acid. Part 1: Effects of lactic acid and hydrophiling agents on physical and chemical properties of methylcellulose gels. Pharmazie 51, 989 – 990.
• 5. Małolepsza-Jarmołowska K, Kubis AA; (1999) Studies on gynaecological hydrophilic lactic acid preparations. Part 2: Effects of Eudragit® E-100 on properties of methylcellulose gels. Pharmazie 54, 441 – 443.
• 6. Małolepsza-Jarmołowska K, Kubis AA; (2000) Studies on gynaecological hydrophilic lactic acid preparations. Part 3: Effects of chitosan on the properties of methylcellulose gels. Pharmazie 55, 610 – 611.
• 7. Małolepsza-Jarmołowska K, Kubis AA; (2001) Studies on gynaecological hydrophilic lactic acid preparations. Part 4: Effects of polyvinyl pyrrolidone K-90 on properties of methylcellulose gels. Pharmazie 56, 160 – 162.
• 8. Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 5: The use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 260 – 262.
• 9. Małolepsza-Jarmołowska K, Kubis AA, Hirnle L; (2003) Studies on gynaecological hydrophilic lactic acid preparations. Part 6: Use of Eudragit® E-100 as lactic acid carrier in intravaginal tablets. Pharmazie 58, 334 – 336.
• 10. Małolepsza-Jarmołowska K; (2006) Studies on gynaecological hydrophilic lactic acid preparations. Part 7: Use of chitosan as lactic acid carrier in intravaginal tablets (globuli vaginales). Pharmazie 61, 780 – 782.
• 11. Małolepsza-Jarmołowska K; (2007) Studies on gynaecological hydrophilic lactic acid preparations. Part 8: Use of chitosan as lactic acid carrier in intravaginal tablets. Acta Pol. Pharm. 64, 69 – 72.
• 12. Małolepsza-Jarmołowska K; (2010) The effect of poloxamer 407 on the properties of hydrophilic gels containing lactic acid complexed with chitosan. Monograph vol. XV ed. by M. Jaworska “Progress on Chemistry and Application of Chitin and Its Derivatives” 15, 143 – 148.

• Document Type: article